Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GONB for Acute Migraine Attacks
NCT03159000Phase 4Withdrawn
- Sponsor
- Thomas Jefferson University
- Start
- May 2017
- Primary completion
- Dec 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in migraine comparing GONB (Lidocaine/Bupivacaine) with Placebo (Saline) (2 arms). Primary endpoint: Percentage of subjects experiencing headache improvement at 2 hours. Planned start May 2017; status: withdrawn.
02
Drugs
lidocainebupivacaine
03
Conditions
migraine
Beyond the preview
Go deeper on NCT03159000.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03159000.